Document is current
Any future updates will be listed below
-
Authors
Lowell, Jeffrey A.
Sharma, Garvita
Chua, Vincent
Ben-Horin, Shomron
Swaminath, Arun
Sultan, Keith
- License Information
-
More Information
Article History
Received: 22 April 2024
Accepted: 29 May 2024
First Online: 14 June 2024
Declarations
:
: Shomron Ben-Horin has received Advisory Board and/or consulting fees from Abbvie, Takeda, Janssen, Celltrion, Pfizer, GSK, Ferring, Novartis, Roche, Gilead, NeoPharm, PredictaMed, Galmed, Evinature, and Eli Lilly, holds stocks/options in Galmed, Evinature, Alma Therapeutics and PredictaMed, and received research support from Abbvie, Takeda, Janssen, Celltrion, Pfizer, and Galmed. None of these financial interests are directly or indirectly related to the research or content discussed in this manuscript.
: All authors have approved submission of the manuscript final draft. Deidentified individual participant data that underlie the results reported in this article will be made available upon reasonable request. Data will be shared with investigators whose proposed use of the data has been approved by an Independent Review Committee identified for this purpose.
